Adjuvant properties of IFN-γ and GM-CSF in the scFv6.C4 DNA vaccine against CEA-expressing tumors.

Gene Therapy
Bianca Ferrarini ZanettiSang Won Han

Abstract

Tumor-associated carcinoembryonic antigen (CEA) is a natural target for vaccines against colorectal cancers. Our previous experience with a DNA vaccine with scFv6.C4, a CEA surrogate, showed a CEA-specific immune response with 40% of tumor-free mice after challenge with B16F10-CEA and 47% with MC38-CEA cells. These percentages increased to 63% after using FrC as an adjuvant. To further enhance the vaccine efficacy, we tested GM-CSF and IFNγ as adjuvants. C57BL/6J-CEA2682 mice were immunized 4 times with uP-PS/scFv6.C4, uP-PS/scFv6.C4 + uP-IFNγ, or uP-PS/scFv6.C4 + uP-GMCSF. After one week, the mice were challenged with MC38-CEA, and tumor growth was monitored over 100 days. Immunization with scFv6.C4 and scFv6.C4 + GM-CSF resulted in a gradual increase in the anti-CEA antibody titer, while scFv6.C4 + IFNγ immunization led to a rapid and sustained increase in the titer. The addition of IFNγ also induced higher CD4 + and CD8 + responses. When challenged, almost 80% of the scFv6.C4 + IFNγ-vaccinated mice did not develop tumors, while the others had a significant tumor growth delay. The probability of being tumor-free was 2700% higher using scFv6.C4 + IFNγ than scFv6.C4. The addition of GM-CSF had no additional effect on tumor prot...Continue Reading

References

Dec 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A TemperoH D Kay
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M WiesenfeldR Pazdur
May 15, 1994·International Journal of Cancer. Journal International Du Cancer·J Z de MoraesJ P Mach
Jan 1, 1993·Advances in Experimental Medicine and Biology·R M SteinmanK Inaba
Jan 1, 1993·Annual Review of Immunology·M A Farrar, R D Schreiber
Mar 20, 2002·Cytokine & Growth Factor Reviews·Hiroaki IkedaRobert D Schreiber
May 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gustav J UllenhagHåkan Mellstedt
Dec 14, 2004·Cancer Immunology, Immunotherapy : CII·Rosalyn D BlumenthalDavid M Goldenberg
Sep 23, 2006·Journal of Biotechnology·Graciela Conceição PignatariSang Won Han
Jun 26, 2007·Scandinavian Journal of Immunology·K HallermalmB Wahren
Feb 6, 2009·The Journal of Gene Medicine·Chester Bittencourt SacramentoSang Won Han
Jan 16, 2010·Annals of the New York Academy of Sciences·Catriona H T MillerHoward A Young
Apr 2, 2010·Seminars in Immunology·Cheryl Lai-Lai ChiangGeorge Coukos
May 11, 2010·Expert Review of Vaccines·Kevin S CliveGeorge E Peoples
Nov 14, 2013·Expert Review of Vaccines·Vijaya B JoshiAliasger K Salem
Dec 4, 2016·Cancer Immunology, Immunotherapy : CII·Priscila M A DenapoliSang W Han
Jan 9, 2020·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.